137 related articles for article (PubMed ID: 38470968)
1. Mycosis fungoides: successful re-treatment with brentuximab vedotin.
James M; Nakamura M; Whittaker S; Morris S
Br J Dermatol; 2024 May; 190(6):929-930. PubMed ID: 38470968
[No Abstract] [Full Text] [Related]
2. Treatment of mycosis fungoides with brentuximab vedotin: Assessing CD30 expression by immunohistochemistry and quantitative real-time polymerase chain reaction.
Hofer V; Maurus K; Houben R; Schrama D; Roth S; Goebeler M; Geissinger E; Rosenwald A; Wobser M
J Cutan Pathol; 2022 Mar; 49(3):314-317. PubMed ID: 34854114
[No Abstract] [Full Text] [Related]
3. Poikilodermatous mycosis fungoides with CD30-positive large cell transformation successfully treated by brentuximab vedotin.
Popadic S; Lekic B; Tanasilovic S; Bosic M; Nikolic M
Dermatol Ther; 2020 Jan; 33(1):e13152. PubMed ID: 31743946
[TBL] [Abstract][Full Text] [Related]
4. Safety and effectiveness of the combination of systemic gemcitabine and intralesional brentuximab vedotin in tumor-stage mycosis fungoides.
Torre-Castro J; Recio-Monescillo M; Castillo Bazan E; Díaz de la Pinta J; Rodríguez Pinilla M; Requena L; Córdoba R
Int J Dermatol; 2024 Jun; 63(6):828-830. PubMed ID: 38419393
[No Abstract] [Full Text] [Related]
5. RF - Brentuximab as Treatment for CD30
Morgado-Carrasco D; Combalia A; Estrach Panella T
Actas Dermosifiliogr (Engl Ed); 2019 Nov; 110(9):769-770. PubMed ID: 31151669
[No Abstract] [Full Text] [Related]
6. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
Kim YH; Prince HM; Whittaker S; Horwitz SM; Duvic M; Bechter O; Sanches JA; Stadler R; Scarisbrick J; Quaglino P; Zinzani PL; Wolter P; Eradat H; Pinter-Brown LC; Ortiz-Romero PL; Akilov OE; Trotman J; Taylor K; Weichenthal M; Walewski J; Fisher D; McNeeley M; Gru AA; Brown L; Palanca-Wessels MC; Lisano J; Onsum M; Bunn V; Little M; Trepicchio WL; Dummer R
Eur J Cancer; 2021 May; 148():411-421. PubMed ID: 33794441
[TBL] [Abstract][Full Text] [Related]
7. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
Goyal A; Hordinsky M; Lazaryan A
Dermatol Ther; 2019 Mar; 32(2):e12835. PubMed ID: 30659762
[TBL] [Abstract][Full Text] [Related]
8. Treatment of CD30-Negative Refractory Mycosis Fungoides With Brentuximab Vedotin.
Zhang C; Chairatchaneeboon M; Haun P; Landsburg D; Kim EJ
JAMA Dermatol; 2018 Jan; 154(1):109-110. PubMed ID: 29167875
[No Abstract] [Full Text] [Related]
9. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
Kim YH; Tavallaee M; Sundram U; Salva KA; Wood GS; Li S; Rozati S; Nagpal S; Krathen M; Reddy S; Hoppe RT; Nguyen-Lin A; Weng WK; Armstrong R; Pulitzer M; Advani RH; Horwitz SM
J Clin Oncol; 2015 Nov; 33(32):3750-8. PubMed ID: 26195720
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of brentuximab vedotin before and after allogeneic stem-cell transplantation in the management of transformed mycosis fungoides.
André R; Ram-Wolff C; Battistella M; Peffault de Latour R; Petit A; Bouaziz JD; Brice P; Bagot M; de Masson A
Br J Dermatol; 2020 Jun; 182(6):1503-1504. PubMed ID: 31854457
[No Abstract] [Full Text] [Related]
11. New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia.
Pileri A; Starace M; Alessandrini A; Casadei B; Zinzani PL; Piraccini BM
Br J Dermatol; 2019 Jun; 180(6):1535-1536. PubMed ID: 30561000
[No Abstract] [Full Text] [Related]
12. Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations.
Geller S; Pulitzer M; Horwitz SM; Moskowitz AJ; Myskowski PL
J Dtsch Dermatol Ges; 2019 Feb; 17(2):186-188. PubMed ID: 30549439
[No Abstract] [Full Text] [Related]
13. Tumor-stage mycosis fungoides in palmoplantar localization with large-cell transformation and partial CD30 expression shows complete response to brentuximab vedotin.
Pham AK; Carter JB; Ratcliffe NR; Fuld AD; Lansigan F; Burnside NJ; Guill MA; Zug KA; Jarvis LA; LeBlanc RE
J Cutan Pathol; 2018 Jun; 45(6):458-462. PubMed ID: 29512830
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the peripheral neuropathy associated with brentuximab vedotin treatment of Mycosis Fungoides and Sézary Syndrome.
Corbin ZA; Nguyen-Lin A; Li S; Rahbar Z; Tavallaee M; Vogel H; Salva KA; Wood GS; Kim YH; Nagpal S
J Neurooncol; 2017 May; 132(3):439-446. PubMed ID: 28271282
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Brentuximab Vedotin in advanced cutaneous T-Cell lymphomas patients.
Papadavid E; Kapniari E; Marinos L; Nikolaou V; Oikonomidi A; Georgakopoulos J; Stratigos A; Kouloulias V; Pappa V
J Eur Acad Dermatol Venereol; 2019 May; 33(5):e223-e225. PubMed ID: 30821007
[No Abstract] [Full Text] [Related]
16. Brentuximab vedotin in CD30
Enos TH; Feigenbaum LS; Wickless HW
Int J Dermatol; 2017 Dec; 56(12):1400-1405. PubMed ID: 28762479
[TBL] [Abstract][Full Text] [Related]
17. [Management of mycosis fungoide : focus on brentuximab vedotin].
Lebas E; Collins P; Bonnet C; Libon F; Dezfoulian B; Nikkels AF
Rev Med Liege; 2021 Apr; 76(4):224-231. PubMed ID: 33830684
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Anaplastic Large-Cell Lymphoma with Dramatic Response to Brentuximab Vedotin.
Şahin M; Miskioğlu M; İnanır I; Akar H; Neşe N; Temiz P; Aydoğdu İ
Turk J Haematol; 2021 Feb; 38(1):85-87. PubMed ID: 33504137
[No Abstract] [Full Text] [Related]
19. [Ulceration of lymphomatous skin lesions in a patient with Sezary syndrome treated with brentuximab-vedotin].
Maitrepierre F; Schissler C; Cribier B; Lipsker D
Ann Dermatol Venereol; 2020 Mar; 147(3):198-201. PubMed ID: 31959414
[TBL] [Abstract][Full Text] [Related]
20. An Elusive Case of Mycosis Fungoides: Case Report and Review of the Literature.
Pallazola VA; Deib G; Abha S; Geha RM; Kobayashi K
J Gen Intern Med; 2019 Nov; 34(11):2669-2674. PubMed ID: 31388911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
